Sonoma Pharmaceuticals (SNOA) Non-Current Assets (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Non-Current Assets of $1.9 million for Q1 2026, up 77.99% year-over-year from $1.0 million in Q1 2025, and up 25.85% quarter-over-quarter from $1.5 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Non-Current Assets (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Non-Current Assets history runs 16 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 77.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $6.2 million (up 11.49% YoY), while the FY2026 annual figure was $1.9 million, up 77.99% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.9 million, up from $1.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $2.7 million in Q4 2022, with the low at $1.0 million in Q1 2025.
- The 5-year median for Non-Current Assets is $2.1 million (2023), against an average of $1.9 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 52.33% in 2025, then surged 77.99% in 2026.
- Sonoma Pharmaceuticals' Non-Current Assets stood at $2.7 million in 2022, then slipped by 21.51% to $2.1 million in 2023, then sank by 39.13% to $1.3 million in 2024, then climbed by 14.75% to $1.5 million in 2025, then rose by 25.85% to $1.9 million in 2026.
- Business Quant data shows SNOA's Non-Current Assets at $1.9 million in Q1 2026, $1.5 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.75 Mn |
| Mar 31, 2024 | 2.19 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 2.70 Mn |
| Sep 30, 2022 | 2.57 Mn |
| Jun 30, 2022 | 2.34 Mn |
| Mar 31, 2022 | 2.42 Mn |
| Dec 31, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.81 Mn |